Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS107 in moderate to severe atopic dermatitis
NCT03817190Phase 2Terminated
- Sponsor
- DS Biopharma
- Start
- Sep 2019
- Primary completion
- Sep 2020
- Modality
- Transdermal Patches, Orthosteric Ligands, Hydrogel Systems
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing 2g Oral DS107 with Placebo (2 arms). Primary endpoints: Proportion of Patients Achieving vIGA-AD 0 or 1 and Decrease of >=2 Points at 16 weeks and Proportion of Patients Achieving EASI-75 at 16 weeks. Started Sep 2019; status: terminated.
02
Drugs
DS107E
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03817190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03817190.